CRISPR Therapeutics AG (CRSP) Accumulated Depreciation (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Accumulated Depreciation data on file, last reported at $95.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation rose 23.87% year-over-year to $95.3 million; the trailing twelve-month figure through Mar 2026 stood at $95.3 million (up 23.87% YoY), and the FY2025 full-year result was $91.1 million, up 25.99% from the prior year.
• Accumulated Depreciation rose to $95.3 million in Q1 2026, from $91.1 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $95.3 million in Q1 2026 to a low of $28.0 million in Q3 2022.
• A 5-year average of $60.8 million and a median of $58.3 million in 2024 frame the typical range for Accumulated Depreciation.
• Peak annual rise in Accumulated Depreciation reached 85.67% in 2022, while the deepest fall reached 14.8% in 2022.
• Tracing CRSP's Accumulated Depreciation over 5 years: stood at $33.8 million in 2022, then soared by 57.94% to $53.4 million in 2023, then surged by 35.26% to $72.3 million in 2024, then rose by 25.99% to $91.1 million in 2025, then advanced by 4.71% to $95.3 million in 2026.
• Business Quant data shows CRSP's Accumulated Depreciation at $95.3 million in Q1 2026, $91.1 million in Q4 2025, and $85.6 million in Q3 2025.